Clik here to view.
Immunogenicity of mRNA COVID-19 Vaccines at 4 and 12 Weeks Post Full...
Background/Purpose: Emerging evidence indicates that immunosuppressive therapies may result in reduced immunogenicity –and presumably reduced efficacy- following vaccination with mRNA COVID-19...
View ArticleClik here to view.
Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised...
Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether...
View ArticleClik here to view.
Depletion of KLRG1+ T Cells in a First-in-human Clinical Trial of ABC008 in...
Background/Purpose: Inclusion body myositis (IBM), a relentlessly progressive autoimmune skeletal muscle disease, has no effective available pharmacological therapy. A prominent feature of IBM on...
View ArticleClik here to view.
Comparative Safety of Gout “Treat-to-target” and “Usual Care” Treatment...
Background/Purpose: Rheumatology societies recommend serum-urate (SU)-driven treat-to-target (TTT) strategies for the management of gout. However, cardiovascular (CV) safety of urate-lowering therapy...
View ArticleRituximab versus Conventional Therapeutic Strategy for Remission Induction in...
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an eosinophilic ANCA-associated vasculitis.Glucocorticoids, alone or in combination with cyclophosphamide in severe forms,...
View ArticleClik here to view.
Phase 2 Study Results from a Randomized, Double-blind, Placebo-controlled,...
Background/Purpose: Gout can be effectively managed by inhibiting synthesis of uric acid. Tigulixostat is a novel non-purine selective xanthine oxidase inhibitor which lowers production of uric acid...
View ArticleClik here to view.
Efficacy of Emapalumab, an Anti-IFNγ Antibody in Patients with Macrophage...
Background/Purpose: MAS is a life-threatening complication of rheumatic diseases, occurring most frequently in sJIA. The mainstay of MAS treatment is high dose GCs; however, GCs do not always provide...
View ArticleClik here to view.
SARS-CoV-2 Infections Among Vaccinated Individuals with Rheumatic Disease:...
Background/Purpose: While COVID-19 vaccinations are a critical tool to prevent severe infections, poor immunogenicity in immunocompromised people threatens vaccine effectiveness. We analyzed clinical...
View ArticleClik here to view.
Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group,...
Background/Purpose: Little is known about glucocorticoid-sparing agents in giant cell arteritis (GCA) except for IL-6 inhibition. Secukinumab (SEC) has shown significant improvements in the signs and...
View ArticleClik here to view.
COVID-19 Vaccine Antibody Responses in Patients Treated with B-Cell Agents...
Background/Purpose: Optimal COVID-19 vaccine responses are necessary to protect against severe infection. Patients with systemic rheumatic diseases (SRD) are at risk for not mounting adequate immune...
View ArticleClik here to view.
Humoral and Cellular Immune Responses to a Second Dose of COVID-19 Vaccine...
Background/Purpose: COVID-19 vaccines have robust immunogenicity in the general population. Data on individuals with immune-mediated inflammatory diseases who are taking immunosuppressants remains...
View ArticleAdditional Heterologous versus Homologous Booster Vaccination in...
Background/Purpose: Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)-induced coronavirus disease 2019 (COVID-19) has led to exponentially rising mortality, particularly in immunosuppressed...
View ArticleClik here to view.
Immunogenicity of mRNA COVID-19 Vaccines at 4 and 12 Weeks Post Full...
Background/Purpose: Emerging evidence indicates that immunosuppressive therapies may result in reduced immunogenicity –and presumably reduced efficacy- following vaccination with mRNA COVID-19...
View ArticleClik here to view.
Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised...
Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether...
View ArticleClik here to view.
A Predictive Diagnostic Model for IgA Vasculitis Based on a Metabolomic Approach
Background/Purpose: IgA vasculitis is a rare systemic disease that is life-threatening mainly due to digestive or renal involvement. To date, there is no reliable diagnostic marker. The objective was...
View ArticleClik here to view.
Effect of Avacopan, a Selective C5a Receptor Inhibitor, on Kidney Function in...
Background/Purpose: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis is a life- or organ-threatening condition in which patients experience severe inflammation of small blood...
View ArticleClik here to view.
Depletion of KLRG1+ T Cells in a First-in-human Clinical Trial of ABC008 in...
Background/Purpose: Inclusion body myositis (IBM), a relentlessly progressive autoimmune skeletal muscle disease, has no effective available pharmacological therapy. A prominent feature of IBM on...
View ArticleClik here to view.
Comparative Safety of Gout “Treat-to-target” and “Usual Care” Treatment...
Background/Purpose: Rheumatology societies recommend serum-urate (SU)-driven treat-to-target (TTT) strategies for the management of gout. However, cardiovascular (CV) safety of urate-lowering therapy...
View ArticleRituximab versus Conventional Therapeutic Strategy for Remission Induction in...
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an eosinophilic ANCA-associated vasculitis.Glucocorticoids, alone or in combination with cyclophosphamide in severe forms,...
View ArticleClik here to view.
Phase 2 Study Results from a Randomized, Double-blind, Placebo-controlled,...
Background/Purpose: Gout can be effectively managed by inhibiting synthesis of uric acid. Tigulixostat is a novel non-purine selective xanthine oxidase inhibitor which lowers production of uric acid...
View Article